Cost-effective, high-yield production system for human-like blood-clotting factors for haemophilia therapy

Datum: 3.8.2015

Summary:
An Austrian university has developed a production system in fungi to produce an enzymatically active recombinant blood clotting factor. These factors can essentially reduce the risk of blood infections during haemophilia therapy. The world-wide new development enables a stable production of blood clotting factors, cheaper and higher yielding than human-based factor concentrates. They are looking for industrial partners for licence agreements, commercial and technical cooperation agreements.
Reference:	TOAT20150529001
Country:	Austria
Submitted:	May 29 2015
Updated:	Jul 22 2015
	View Partnering Opportunity

KEYWORDS
Market:	Anatomy, Pathology, Immunology, Physiology , Other medical/health related (not elsewhere classified) , Other therapeutic (including defibrillators)
Technology:	Enzyme Technology, Microbiology , Pharmaceutical Products / Drugs
NACE:	Post-secondary non-tertiary education, Tertiary education